Cystic Fibrosis Foundation - Click here for homepage
Stay Informed  |  Volunteer  |  Clinical Trials

In This Section

Quick Links

Find a Chapter


Study Name: Phase 3 Study of the Safety and Effectiveness of ULTRASE MT20 for Pancreatic Insufficiency
Study Type: Interventional
Intervention Category: Nutritional-GI Therapies
Study Sponsor: Axcan
Study Phase: 3
Recruitment Status: Trial Completed
Study Drug(s): Ultrase MT20
Number of Participants Being Recruited: 30
Single / Multi-Center: Multi-Center
This study will assess the safety and efficacy of a pancreatic enzyme capsule designed for the absorption of nutrients in patients with CF. Approximately 90 percent of people with CF need to take pancreatic enzymes to help them absorb fat and protein properly. Pancreatic enzyme supplements help CF patients to enhance digestion, improve growth, reduce gastrointestinal problems, and contribute to general nutritional health. In addition, use of pancreatic enzymes has played a significant role in increasing the lifespan of people with CF. In the study, individuals will receive either oral capsules of ULTRASE MT (a porcine pancreatic enzyme) or a placebo. Both groups will consume a specific amount of fat and protein. Resulting amounts of fat and protein absorbed will be measured in both groups to determine the efficacy of the enzyme.
Age: >= 7 Years
FEV1: Not Applicable
P. aeruginosa status: Not applicable
B. cepacia status: Not applicable
Other Primary Eligibility Requirements:

Note: Detailed eligibility criteria information may be available on If a specific trial listing for this trial is available, a link to the specific listing will be present in the "More Information" section below.
Sponsor Contact Information: Grondin, Josee
(450) 467-5138 X2428
Trial Specific Link on
Clinical Research Terms Glossary: Click here
Primary Efficacy:

Thirty-one CF patients (Age >/=7 years) with exocrine pancreatic insufficiency were randomized into this Phase 3 crossover study that compared efficacy and safety of a new formulation of pancrealipase 20,000 IU lipase/capsule (Ultrase® MT-20) vs placebo. During two evaluation periods (6-7 days), patients maintained individualized high-fat diets and received pancrealipase at doses established during a stabilization period or placebo and then crossed over to the opposite treatment. MT-20 significantly increased mean CFA% (coefficient of fat absorption) and mean CNA% (coefficient of nitrogen absorption), +34.7% and 25.7%, respectively; p<0.0001 for both.

Secondary Efficacy:

The pancrealipase also reduced stool frequency and improved stool consistency compare with placebo.


Patients reported more AEs while on placebo (109 vs 33 while on pancrealipase). The most frequently reported AEs were GI and consistent with CF.


2010;2010(Article ID 898193)

Back to top